Romosozumab
Romosozumab, sold under the brand name Evenity (/ɪˈvɛnɪti/ ih-VENN-ih-tee or with the pin-pen merger, /ɪˈvɪnɪti/ ih-VINN-ih-tee), is a medication used to treat osteoporosis.[14] Currently, the drug contains a FDA boxed warning on its labeling stating that it may increase the risk of heart attack, stroke and cardiovascular death and should not be used in patients who have had a heart attack or stroke within the previous year.[15] In a large real-world study, prescription of romosozumab was associated with less adverse cardiovascular events compared to other osteoanabolic therapies.[16] Romosozumab was approved for medical use in Japan in January 2019,[10] the United States in April 2019[10] and the European Union in December 2019.[19] The UK's National Institute for Health and Care Excellence (NICE) decided to recommend romosozumab for use in England and Wales.